At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 278 enrolled
Drug / intervention
Non-selective NSAIDS +1 moredrug
Likely dose
Celecoxib 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Randomized Multicenter Comparative Study On Celecoxib Efficacy And Safety Versus Non-Selective NSAID In Acute Pain Due To Ankle Sprain
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Mar 13, 2007·Updated Feb 21, 2021
In Brief
A Phase 4 clinical trial evaluating Non-selective NSAIDS and Celecoxib for Ankle Sprain. Completed, enrolled 278 participants across 16 sites in 8 countries.
Detailed Summary
To assess the efficacy of celecoxib loading dose of 400mg followed by 200 mg twice a day (BID) versus oral non-selective NSAIDs in acute pain due to ankle sprain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkle Sprain
CountriesBrazil, Costa Rica, Ecuador, Egypt, Jordan, Mexico, Panama, Peru
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartMay 2007
Primary CompletionApr 2008
TodayJul 2026
First PostedMar 13, 2007
Enrollment StartMay 1, 2007
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.3 years ago
Interventions
Non-selective NSAIDSdrug
Non-selective NSAIDs administered at usual (standard) doses.
Celecoxibdrug
celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.